EGFR binding molecules
US11629193B2 · kind B2 · utility
9Cited by
10References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 19, 2017 |
| Grant date | Apr 18, 2023 |
| Priority date | — |
| Expiry date | Aug 6, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2318/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application relates to specific binding members which bind the human epidermal growth factor receptor (EGFR). The specific binding members preferably comprise an EGFR antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members are expected to find application in the treatment of cancers expressing EGFR.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.